サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442860

脂質異常症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2023年～2031年）

Lipid Disorder Treatment Market (Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, and Other Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 170 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
脂質異常症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2023年～2031年）
出版日: 2024年01月22日
発行: Transparency Market Research
ページ情報: 英文 170 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脂質異常症治療市場 - レポート対象範囲

世界の脂質異常症治療市場に関するTMRのレポートでは、過去と現在の成長動向、および2023年～2031年の予測期間中の市場指標の貴重な洞察を得る機会を調査しています。このレポートは、世界の脂質異常症治療市場の2017年～2031年の期間の収益を提供し、2023年を基準年、2031年を予測年とみなします。また、2023年～2031年の世界の脂質異常症治療市場の複合年間成長率（CAGR %）も提供しています。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、脂質異常症治療市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の脂質異常症治療市場の競合情勢を詳しく掘り下げています。世界の脂質異常症治療市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の脂質異常症治療市場企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測（2017年～2031年）

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19パンデミックが業界に与える影響

第6章 世界市場の分析と予測：医薬品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：医薬品タイプ別（2017年～2031年）
    • アトルバスタチン
    • フルバスタチン
    • ロスバスタチン
    • シンバスタチン
    • プラバスタチン
    • その他の医薬品
  • 市場魅力度分析：医薬品タイプ別

第7章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別（2017年～2031年）
    • 小売薬局
    • 院内薬局
    • オンライン薬局
  • 市場魅力度分析：流通チャネル別

第8章 世界市場の分析と予測：症状別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：症状別（2017年～2031年）
    • 家族性複合型高脂血症
    • 家族性欠損アポリポタンパク質B-100
    • 家族性ジスベタリポタンパク血症
    • 家族性高トリグリセリド血症
    • ヘテロ接合性家族性高コレステロール血症
    • その他の症状
  • 市場魅力度分析：症状別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別（2017年～2031年）
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業：競合マトリクス（企業階層・規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • AstraZeneca
    • Merck &Co., Inc.
    • Emcure Pharmaceuticals Ltd.
    • Teva Pharmaceuticals Industries Ltd.
    • Mylan NV
    • Kowa Pharmaceuticals America, Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceuticals Industries Ltd.
    • Wockhardt Limited
図表

List of Tables

  • Table 01: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 04: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 07: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 09: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 13: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 15: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 17: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 19: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 21: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 23: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017-2031

List of Figures

  • Figure 01: Global Lipid Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Drug Type, 2022
  • Figure 03: Global Lipid Disorder Treatment Market Value Share, by Drug Type, 2022
  • Figure 04: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 05: Global Lipid Disorder Treatment Market Value Share, by Distribution Channel, 2022
  • Figure 06: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Indication, 2022
  • Figure 07: Global Lipid Disorder Treatment Market Value Share, by Indication, 2022
  • Figure 08: Global Lipid Disorder Treatment Market Value Share, by Region, 2022
  • Figure 09: Global Lipid Disorder Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 11: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 12: Global Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 13: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 14: Global Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 15: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 16: Global Lipid Disorder Treatment Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Lipid Disorder Treatment Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 21: North America Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 22: North America Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 23: North America Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 24: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 26: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 27: Europe Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 31: Europe Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 32: Europe Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 33: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 34: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 35: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 36: Asia Pacific Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 40: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 41: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 42: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 43: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 44: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 45: Latin America Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 49: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 50: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 51: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 52: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 53: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 54: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 58: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 59: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 60: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 61: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 62: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023-2031
目次
Product Code: TMRGL40640

Lipid Disorder Treatment Market - Scope of Report

TMR's report on the global lipid disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid disorder treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid disorder treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lipid disorder treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid disorder treatment market.

The report delves into the competitive landscape of the global lipid disorder treatment market. Key players operating in the global lipid disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid disorder treatment market profiled in this report.

Key Questions Answered in Global lipid disorder treatment Market Report:

  • What is the sales/revenue generated by lipid disorder treatment across all regions during the forecast period?
  • What are the opportunities in the global lipid disorder treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Lipid Disorder Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global lipid disorder treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lipid disorder treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid disorder treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lipid Disorder Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lipid Disorder Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Lipid Disorder Treatment Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Atorvastatin
    • 6.3.2. Fluvastatin
    • 6.3.3. Rosuvastatin
    • 6.3.4. Simvastatin
    • 6.3.5. Pravastatin
    • 6.3.6. Other Drugs
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Lipid Disorder Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Lipid Disorder Treatment Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Familial Combined Hyperlipidemia
    • 8.3.2. Familial Defective Apolipoprotein B-100
    • 8.3.3. Familial Dysbetalipoproteinemia
    • 8.3.4. Familial Hypertriglyceridemia
    • 8.3.5. Heterozygous Familial Hypercholesterolemia
    • 8.3.6. Other Indications
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Lipid Disorder Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Lipid Disorder Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2017-2031
    • 10.3.1. Atorvastatin
    • 10.3.2. Fluvastatin
    • 10.3.3. Rosuvastatin
    • 10.3.4. Simvastatin
    • 10.3.5. Pravastatin
    • 10.3.6. Other Drugs
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Hospital Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Indication, 2017-2031
    • 10.5.1. Familial Combined Hyperlipidemia
    • 10.5.2. Familial Defective Apolipoprotein B-100
    • 10.5.3. Familial Dysbetalipoproteinemia
    • 10.5.4. Familial Hypertriglyceridemia
    • 10.5.5. Heterozygous Familial Hypercholesterolemia
    • 10.5.6. Other Indications
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Distribution Channel
    • 10.7.3. By Indication
    • 10.7.4. By Country

11. Europe Lipid Disorder Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2017-2031
    • 11.3.1. Atorvastatin
    • 11.3.2. Fluvastatin
    • 11.3.3. Rosuvastatin
    • 11.3.4. Simvastatin
    • 11.3.5. Pravastatin
    • 11.3.6. Other Drugs
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Hospital Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Indication, 2017-2031
    • 11.5.1. Familial Combined Hyperlipidemia
    • 11.5.2. Familial Defective Apolipoprotein B-100
    • 11.5.3. Familial Dysbetalipoproteinemia
    • 11.5.4. Familial Hypertriglyceridemia
    • 11.5.5. Heterozygous Familial Hypercholesterolemia
    • 11.5.6. Other Indications
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Distribution Channel
    • 11.7.3. By Indication
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Lipid Disorder Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2017-2031
    • 12.3.1. Atorvastatin
    • 12.3.2. Fluvastatin
    • 12.3.3. Rosuvastatin
    • 12.3.4. Simvastatin
    • 12.3.5. Pravastatin
    • 12.3.6. Other Drugs
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Hospital Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Indication, 2017-2031
    • 12.5.1. Familial Combined Hyperlipidemia
    • 12.5.2. Familial Defective Apolipoprotein B-100
    • 12.5.3. Familial Dysbetalipoproteinemia
    • 12.5.4. Familial Hypertriglyceridemia
    • 12.5.5. Heterozygous Familial Hypercholesterolemia
    • 12.5.6. Other Indications
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Distribution Channel
    • 12.7.3. By Indication
    • 12.7.4. By Country/Sub-region

13. Latin America Lipid Disorder Treatment Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2017-2031
    • 13.3.1. Atorvastatin
    • 13.3.2. Fluvastatin
    • 13.3.3. Rosuvastatin
    • 13.3.4. Simvastatin
    • 13.3.5. Pravastatin
    • 13.3.6. Other Drugs
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Hospital Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Indication, 2017-2031
    • 13.5.1. Familial Combined Hyperlipidemia
    • 13.5.2. Familial Defective Apolipoprotein B-100
    • 13.5.3. Familial Dysbetalipoproteinemia
    • 13.5.4. Familial Hypertriglyceridemia
    • 13.5.5. Heterozygous Familial Hypercholesterolemia
    • 13.5.6. Other Indications
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Distribution Channel
    • 13.7.3. By Indication
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Lipid Disorder Treatment Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2017-2031
    • 14.3.1. Atorvastatin
    • 14.3.2. Fluvastatin
    • 14.3.3. Rosuvastatin
    • 14.3.4. Simvastatin
    • 14.3.5. Pravastatin
    • 14.3.6. Other Drugs
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Retail Pharmacies
    • 14.4.2. Hospital Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Indication, 2017-2031
    • 14.5.1. Familial Combined Hyperlipidemia
    • 14.5.2. Familial Defective Apolipoprotein B-100
    • 14.5.3. Familial Dysbetalipoproteinemia
    • 14.5.4. Familial Hypertriglyceridemia
    • 14.5.5. Heterozygous Familial Hypercholesterolemia
    • 14.5.6. Other Indications
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Distribution Channel
    • 14.7.3. By Indication
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Novartis AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AstraZeneca
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co., Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Emcure Pharmaceuticals Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Teva Pharmaceuticals Industries Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Mylan N.V.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Kowa Pharmaceuticals America, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Glenmark Pharmaceuticals Ltd.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Sun Pharmaceuticals Industries Ltd.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Wockhardt Limited
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview